Renaissance Technologies (RenTech)'s APLS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 633,058 shares of Apellis Pharmaceuticals, Inc. (APLS) worth $15.9 M, representing 0.02% of the portfolio. First purchased in 2019-Q1, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in APLS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 711,907 shares. Largest reduction occurred in Q2 2021, reducing 353,302 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Apellis Pharmaceuticals (APLS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apellis Pharmaceuticals (APLS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -89,837 | Reduce 12.43% | 633,058 | $25.12 |
| Q3 2025 | +711,907 | Add 6478.95% | 722,895 | $22.63 |
| Q2 2025 | +10,988 | New Buy | 10,988 | $17.31 |
| Q1 2025 | -271,913 | Sold Out | 0 | $0.00 |
| Q4 2024 | -100,418 | Reduce 26.97% | 271,913 | $31.91 |
| Q3 2024 | +372,331 | New Buy | 372,331 | $28.84 |
| Q3 2023 | -138,513 | Sold Out | 0 | $0.00 |
| Q2 2023 | +138,513 | New Buy | 138,513 | $0.09 |
| Q1 2023 | -187,413 | Sold Out | 0 | $0.00 |
| Q4 2022 | -157,700 | Reduce 45.70% | 187,413 | $0.05 |
| Q3 2022 | +345,113 | New Buy | 345,113 | $68.30 |
| Q3 2021 | -20,211 | Sold Out | 0 | $0.00 |
| Q2 2021 | -353,302 | Reduce 94.59% | 20,211 | $63.18 |
| Q1 2021 | +157,200 | Add 72.67% | 373,513 | $42.91 |
| Q4 2020 | +216,313 | New Buy | 216,313 | $57.20 |
| Q1 2020 | -19,513 | Sold Out | 0 | $0.00 |
| Q4 2019 | +19,513 | New Buy | 19,513 | $30.59 |
| Q2 2019 | -26,200 | Sold Out | 0 | $0.00 |
| Q1 2019 | +26,200 | New Buy | 26,200 | $19.50 |
Renaissance Technologies (RenTech)'s Apellis Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Apellis Pharmaceuticals, Inc. (APLS) in Q1 2019, acquiring 26,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Apellis Pharmaceuticals, Inc. (APLS) for 19 quarters since Q1 2019.
Renaissance Technologies (RenTech)'s largest addition to Apellis Pharmaceuticals, Inc. (APLS) was in Q3 2025, adding 722,895 shares worth $16.36 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 633,058 shares of Apellis Pharmaceuticals, Inc. (APLS), valued at approximately $15.9 M.
As of the Q4 2025 filing, Apellis Pharmaceuticals, Inc. (APLS) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Apellis Pharmaceuticals, Inc. (APLS) was 722,895 shares, as reported at the end of Q3 2025.